SUMMARYA panel of eight neutralizing monoclonal antibodies (MAbs) against the fusion (F) protein of Newcastle disease virus (NDV) has been shown to locate a major antigenic site on the basis of competitive binding assay and additivity index studies. Five epitopes (A 1 to AS) have been located within this site on the F protein of the Beaudette C strain of NDV on the basis of cross-resistance plaque assays of MAb-resistant mutants raised against these MAbs. Epitopes A1, A4 and A5 are distinct; epitope A2 partially overlaps epitope A3. Nucleotide sequence analysis of the F genes of MAbresistant mutants showed that each predicted single amino acid substitutions ranging from amino acid residues 157 to 171 for epitope A4 and at residues 72, 78, 79 and 343 for epitopes A 1, A2, A3 and A5 respectively. These locations indicate that both the F 1 and F2 fragments are involved in the formation of a single antigenic site and suggest the involvement of extensive protein folding in the active form of this F protein.
Nine neutralizing monoclonal antibodies (MAbs), each of which react with the haemagglutinin-neuraminidase (HN) glycoprotein of the Beaudette C strain of Newcastle disease virus (NDV), have been used in competitive binding assays to delineate three non-overlapping antigenic sites A, B and C. Epitopes within these sites have been identified on the basis of cross-reactivity of MAb-resistant mutants against the panel of MAbs, determined by plaque assays and Western blotting. Site A contains three non-overlapping epitopes (A1, A2 and A3). A1 is the only linear epitope; all remaining epitopes are conformational. MAbs which react with epitopes A2 and A3 inhibit neuraminidase activity (NA) when assayed with neuraminlactose. Site B contains three partially overlapping epitopes (B1, B2 and B3) and site C is represented by a single epitope (C1). HN gene sequence analysis of MAb-resistant mutants showed that they each had only single amino acid substitutions which range from amino acid residues 347-460 for site A, 284-325 for site B, and at 481 for the C1 epitope. The apparent molecular mass of the HN glycoprotein of one mutant was increased from 72 to 75 kDa. This correlates well with the creation of an additional potential glycosylation site in this mutant from Asn-Ser-Pro(325) to Asn-Ser-Ser(325).
Bifunctional alkylating agents, such as those based on nitrogen mustard, form important parts of many anti-cancer chemotherapy protocols and are responsible for increased incidences of secondary tumors in successfully treated patients. These drugs generally form a majority of monofunctional DNA adducts, although the bifunctional adducts appear to be necessary for their powerful cytotoxic and antitumor effects. The relative importance of bifunctional as opposed to monofunctional adducts in the varied biological consequences of drug exposure has not been studied in detail, particularly in relation to the role and specificity of biochemical responses to therapy-related DNA damage. A simple method is described for the preparation of useful quantities of a pure monofunctional derivative of the nitrogen mustard-based drug melphalan. Monohydroxymelphalan was prepared by partial hydrolysis, purified by reversed phase chromatography, and characterized by MS, NMR, and HPLC. Contamination with melphalan was =0.2%. The heat labile DNA base adducts formed by monohydroxymelphalan were shown to contain undetectable levels of cross-linked species. The ratio of adenine to guanine adducts was 0.62, similar to the equivalent ratio for melphalan. The sequence-dependent pattern of alkylation of purified DNA was indistinguishable from that of melphalan, but required a higher dose to achieve comparable extents of reaction. The specificities of two monoclonal antibodies that recognize melphalan-DNA adducts were investigated using DNA alkylated with [3H]monohydroxymelphalan. Adducts on this DNA showed similar immunoreactivities to adducts formed by melphalan. This shows clearly that neither antibody was specific for cross-linked adducts and that it is therefore possible to quantify adducts formed by both monohydroxymelphalan and melphalan with high sensitivities. The availability of monohydroxymelphalan in addition to melphalan, together with sensitive immunoassays for adducts on extracted DNA and in individual cells, constitutes a useful system for investigating cellular responses to the DNA modifications formed by a clinically relevant drug.
Monoclonal antibodies were produced that recognized alkali-stabilized modifications of DNA formed by the anticancer drug melphalan in order to permit measurement of melphalan-DNA adducts in individual cells by immunofluorescent staining. Antibody Amp4/42 did not bind to alkali-treated control DNA or to DNA that had been alkylated with melphalan but not exposed to alkali. In a competitive enzyme-linked immunoadsorbent assay using DNA that had been reacted with radioactive melphalan in simple solution a 50% reduction in assay signal was caused by approximately 100 fmol total melphalan-DNA adducts/assay well. This sensitivity was only slightly influenced by heat denaturation of the DNA before alkylation or by the frequency of alkylated sites on DNA. The heat stability of the adducts recognized by Amp4/42 was greatly increased by the alkali-induced change which, in 0.1 M NaOH at 37 degrees C, was complete by 30 min. Amp4/42 appears to recognize a ring-opened structure resulting from alkaline hydrolysis of 7-alkyldeoxyguanosine. Melphalan-DNA adducts formed in mammalian cells showed an alkali-induced increase in immunoreactivity which occurred at a similar rate to that seen in DNA that had been alkylated in simple solution, but their maximum overall immunoreactivity was approximately 10-fold lower. This indicated that in cells the adducts recognized by Amp4/42 were formed or persisted as a smaller proportion of total adducts compared with alkylation of pre-purified DNA in simple solution. This antibody permitted immunofluorescent detection of melphalan-DNA adducts in single cells.
The bifunctional alkylating agent, melphalan, forms adducts on DNA that are recognized by two previously described monoclonal antibodies, MP5/73 and Amp4/42. Immunoreactivity to MP5/73 was lost when alkylated DNA was exposed to alkaline pH, while Amp4/42 only recognized the structures formed after the alkali treatment. Competitive enzyme-linked immunoadsorbent assays (ELISAs) indicated that in 0.01 and 0.1 M NaOH, loss of immunoreactivity to MP5/73 occurred with half-lives that were at least 2-fold longer than half-lives for gain of immunoreactivity to Amp4/42. This supported previously published evidence that Amp4/42 did not simply recognize all the products formed by alkali treatment of adducts that were initially recognized by MP5/73. Adducts recognized by MP5/73 on RNA were considerably more stable at 100 degrees C and pH 7 than adducts on DNA. This was consistent with the hypothesis that immunorecognition involved N7 guanine adducts and ruled out the involvement of phosphotriesters in immunoreactivity. Synthetic oligodeoxyribonucleotides, covalently immobilized onto 96-well plates, were reacted with melphalan and incubated for various periods with alkali, and then the levels of adducts recognized by each antibody in replicate wells were assayed by a direct binding ELISA. Adducts formed on oligodeoxyguanylic acid were recognized very weakly by Amp4/42, unlike other DNA sequences that were tested. Retention of immobilized DNA during alkali treatment was confirmed by immunoassay of cisplatin adducts. Poor recognition by Amp4/42 of adducts in oligodeoxyguanylic acid was confirmed by a competitive ELISA. Amp4/42, unlike MP5/73, efficiently recognized adducts resulting from alkylation of DNA with chlorambucil. It is concluded that the two antibodies recognized melphalan adducts in different DNA sequence environments and that this explains (a) the different alkali stability of immunoreactive adducts and (b) previous results which showed that, in DNA from melphalan-treated cells, adducts recognized by Amp4/42 formed a smaller proportion of total adducts compared to DNA alkylated in vitro. The results presented here indicate that this was caused by a marked cellular influence on the overall sequence-dependent pattern of DNA alkylation or repair.
Summary. Nucleotide sequence analysis of temperature sensitive and "neuraminidase-tolerant" mutants of Newcastle disease virus has identified sites in the haemagglutinin-neuraminidase protein which may be important in folding and function.Newcastle disease virus, family Paramyxoviridae, genus Paramyxovirus, contains two surface glycoproteins, haemagglutinin-neuraminidase (HN), which binds to and cleaves neuraminic acid from host receptors, and fusion protein (F), which is responsible for fusing host and virus membranes. Both glycoproteins are embedded in a lipid bilayer. Closely apposed to this lipid bilayer is the matrix protein (M) which may interact with the cytoplasmic region(s) of the membrane glycoproteins.The temperature sensitive mutant ts53, originally isolated by Dahlberg [5] following nitrous acid mutagenesis of the thermostable strain ofNDV Beaudette C, was earlier shown to possess a thermolabile HN glycoprotein (determined by assaying both haemagglutination and neuraminidase activities), and to produce a matrix protein which was susceptible to proteolytic cleavage in vivo at the non-permissive temperature (42 °C) in CEF [7].To locate the genetic lesion(s) in this non-revertible ts mutant we sequenced the M and HN genes from wild type (wt) and ts53 virions using M and HN gene specific oligonucleotide primers, virion RNA and reverse transcriptase, as described earlier [-21]. In addition, we have isolated "neuraminidase-tolerant" mutants of the Beaudette C strain and sequenced the HN genes of these mutants
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.